Novel Caval Valve Implantation in a Patient With Symptomatic Tricuspid Regurgitation and Right Heart Failure.

Background

Tricuspid regurgitation (TR) is crucial for recurrent cardiac decompensation. Heterotopic transcatheter approaches enable symptomatic treatment of TR in patients who are ineligible for surgery or transcatheter edge-to-edge repair. The TRICENTO G2 prosthesis is a transcatheter bicaval valved stent graft, not yet approved for the market. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY To the best of our knowledge, this is the first published case of successful TRICENTO G2 transcatheter heart valve implantation, performed as compassionate use in an 81-year-old man with symptomatic TR following multiple interventions. No major complications occurred during the procedure, and a short-term functional improvement in right ventricular function resulted. Given intermittent third-degree atrioventricular block, leadless pacemaker implantation was conducted subsequently.

Discussion

The TRICENTO G2 represents a promising treatment option for symptomatic TR. However, wise patient selection and vigilant postprocedural observation are essential. NOVELTY The implementation of the TRICENTO G2 may expand our interventional armamentarium for treating TR. TAKE-HOME MESSAGE The TRICENTO G2 may improve tailored treatment of patients with symptomatic TR and right ventricular dysfunction who are ineligible for approved interventions.